Author Archives: Steve Bryson PhD

Phase 2 Trial Tests Daxdilimab as Potential DLE Therapy

The first patient has been enrolled in RECAST DLE, a Phase 2 study evaluating daxdilimab, a potentially first-in-class therapy for moderate-to-severe discoid lupus erythematosus (DLE), a form of lupus that affects the skin. Horizon Therapeutics, the therapy’s developer, expects to enroll about 100 DLE patients, ages 18–75 whose…

Kira to Test KP-104 With KORU’s Infusion Device in SLE Phase 2 Trial

Kira Pharmaceuticals will test KP-104, an investigational therapy for a blood-clotting disorder associated with systemic lupus erythematosus (SLE), using KORU Medical Systems’ easy-to-use subcutaneous (under-the-skin) Freedom System infusion device. “We selected KORU Medical based on their track record of helping patients receive high-value therapeutics subcutaneously in the…

2 Machine Learning Models Found to Predict Hospitalization in SLE

Using clinical data collected over time, two machine learning computer models were found to accurately predict inpatient hospitalization due to systemic lupus erythematosus (SLE) — the most common form of lupus. One method was most accurate in using short-term clinical assessment data to foretell future hospitalizations, while the other…